Related references
Note: Only part of the references are listed.Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Shelby D. Reed et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
B. Sherrill et al.
BRITISH JOURNAL OF CANCER (2008)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward
Joseph Lipscomb et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study
M. V. Karamouzis et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Stephanie R. Land et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data
DA Revicki et al.
QUALITY OF LIFE RESEARCH (2006)
Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
KJ Yost et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
F Efficace et al.
EUROPEAN JOURNAL OF CANCER (2004)
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study
A Bottomley et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Accounting for deaths in longitudinal studies using the SF-36 - The performance of the physical component scale of the short form 36-item health survey and the PCTD
P Diehr et al.
MEDICAL CARE (2003)
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
S Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
F Cardoso et al.
ANNALS OF ONCOLOGY (2002)
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
KL Kilbridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis
BF Cole et al.
LANCET (2001)
Transforming self-rated health and the SF-36 scales to include death and improve interpretability
P Diehr et al.
MEDICAL CARE (2001)
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer
LE Carlson et al.
BONE MARROW TRANSPLANTATION (2001)
Systematic overview of cost-utility assessments in oncology
CC Earle et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
